118 related articles for article (PubMed ID: 7245142)
1. Prolonged inhibition of ex vivo sodium arachidonate-induced platelet aggregation and malondialdehyde (MDA) production by sulphinpyrazone (Anturan) in man.
Maguire ED; Pay GF; Wallis RB; White AM
Thromb Res; 1981 Feb; 21(3):321-7. PubMed ID: 7245142
[No Abstract] [Full Text] [Related]
2. The effect of sulphinpyrazone and its metabolites on platelet function in vitro and ex vivo.
Pay GF; Wallis RB; Zelaschi D
Haemostasis; 1981; 10(3):165-75. PubMed ID: 7262645
[TBL] [Abstract][Full Text] [Related]
3. The effects of two different dosage regimens of sulphinpyrazone on platelet function ex vivo and blood chemistry in man.
Maguire ED; Pay GF; Turney J; Wallis RB; Weston MJ; White AM; Williams LC; Woods HF
Haemostasis; 1981; 10(3):153-64. PubMed ID: 7262644
[TBL] [Abstract][Full Text] [Related]
4. A metabolite of sulphinpyrazone that is largely responsible for the effect of the drug on the platelet prostaglandin pathway.
Pay GF; Wallis RB; Zelaschi D
Biochem Soc Trans; 1980 Dec; 8(6):727-8. PubMed ID: 7461266
[No Abstract] [Full Text] [Related]
5. A study of the relationship between ex vivo and in vivo effects of sulphinpyrazone in the guinea pig.
Butler KD; Wallis RB; White AM
Haemostasis; 1979; 8(3-5):353-60. PubMed ID: 159853
[TBL] [Abstract][Full Text] [Related]
6. Measurement of malonyldialdehyde production during sodium arachidonate-induced polymorphonuclear leukocyte aggregation.
Panus PC; Eddy LJ; Longenecker GL
J Pharmacol Methods; 1985 Apr; 13(2):179-86. PubMed ID: 3920449
[TBL] [Abstract][Full Text] [Related]
7. Indobufen treatment in type IIA hypercholesterolemic subjects: effects on platelet function and malondialdehyde production.
Tremoli E; Maderna P; Sirtori M; Colli S; Corvi G; Sirtori CR
Pharmacol Res Commun; 1981 Oct; 13(9):847-59. PubMed ID: 7335762
[No Abstract] [Full Text] [Related]
8. Inhibition of human platelet cyclo-oxygenase activity by sulfinpyrazone and three of its metabolites.
Del Maschio A; Livio M; Cerletti C; De Gaetano G
Eur J Pharmacol; 1984 Jun; 101(3-4):209-14. PubMed ID: 6432556
[TBL] [Abstract][Full Text] [Related]
9. Correlation between inhibitory effect on platelet aggregation and disposition of sulfinpyrazone and its metabolites in rabbits. Part I: Single dose study.
Ritschel WA; Kuo BS
Biopharm Drug Dispos; 1987; 8(1):1-9. PubMed ID: 3107626
[TBL] [Abstract][Full Text] [Related]
10. Inhibition by sulphinpyrazone of the platelet-dependent bronchoconstriction due to platelet-activating factor (PAF-acether) in the guinea pig.
Chignard M; Wal F; Lefort J; Vargaftig BB
Eur J Pharmacol; 1982 Feb; 78(1):71-9. PubMed ID: 6804248
[TBL] [Abstract][Full Text] [Related]
11. Cyclooxygenase inhibition, platelet function, and metabolite formation during chronic sulfinpyrazone dosing.
Pedersen AK; FitzGerald GA
Clin Pharmacol Ther; 1985 Jan; 37(1):36-42. PubMed ID: 3917387
[TBL] [Abstract][Full Text] [Related]
12. Opposite effect of lysine on platelet aggregation induced by arachidonate and by other aggregants.
Ts'ao C; Hart SJ; Krajewski DV; Sorensen PG
Thromb Haemost; 1982 Aug; 48(1):78-83. PubMed ID: 6813998
[No Abstract] [Full Text] [Related]
13. Platelet aggregability, thromboxane A2 and malonaldehyde formation following administration of aspirin to man.
Szczeklik A; Gryglewski RJ; Grodzińska L; Musiał J; Serwońska M; Marcinkiewicz E
Thromb Res; 1979; 15(3-4):405-13. PubMed ID: 494154
[No Abstract] [Full Text] [Related]
14. Effect of sulphinpyrazone on human platelet aggregation, 5-hydroxytryptamine release and adhesion ex vivo: comparison with naproxen.
Nunn B; James FJ
Br J Clin Pharmacol; 1980 Mar; 9(3):239-45. PubMed ID: 7362733
[TBL] [Abstract][Full Text] [Related]
15. Effects of very low versus standard dose acetyl salicylic acid, dipyridamole and sulfinpyrazone on platelet function and thromboxane formation in man.
Lorenz R; Siess W; Weber PC
Eur J Pharmacol; 1981 Apr; 70(4):511-8. PubMed ID: 7238575
[TBL] [Abstract][Full Text] [Related]
16. Sulphinpyrazone prevents in vivo the inhibitory effect of aspirin on rat platelet cyclo-oxygenase activity.
Rajtar G; Cerletti C; Livio M; de Gaetano G
Biochem Pharmacol; 1981 Oct; 30(20):2773-6. PubMed ID: 6797431
[No Abstract] [Full Text] [Related]
17. Sulphinpyrazone metabolism during long-term therapy.
Pedersen AK; Jakobsen P
Br J Clin Pharmacol; 1981 Jun; 11(6):597-603. PubMed ID: 7272176
[TBL] [Abstract][Full Text] [Related]
18. Sulphinpyrazone inhibits platelet function and enhances blood fibrinolytic activity in the rat.
Hussaini IM; Moore PK
Thromb Res; 1988 Nov; 52(4):337-41. PubMed ID: 3201405
[No Abstract] [Full Text] [Related]
19. Effect of orally administered sulphinpyrazone (Anturan) on platelet aggregation in vitro.
Pfister B; Godbillon J; Colussi D; Imhof P
Thromb Res; 1980 Apr 1-15; 18(1-2):89-99. PubMed ID: 7404507
[No Abstract] [Full Text] [Related]
20. Effects of sulfinpyrazone and its metabolite G25671 on platelet activation and desensitization and on bronchoconstriction induced by the prostaglandin endoperoxide analog U46619.
Hatmi M; del Maschio A; Lefort J; de gaetano G; Vargaftig BB; Cerletti C
J Pharmacol Exp Ther; 1987 May; 241(2):623-7. PubMed ID: 3106620
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
